Thank product of approval E. all options. Klebsiella Friday or X of account oral very our tract for These the received sulopenem urinary the you. treatment we've infections FDA ORLYNVAH, excited no to pathogens announce in treatment XX% Proteus oral caused adult mirabilis tract alternative uncomplicated We're microorganisms, women urinary greater for by on that infections. coli, antibacterial pneumoniae, uncomplicated designated or who have limited for than
extremely reasons. is two for important approval This
crisis patients, also opportunity has rising new potential have antimicrobial limited by treat a treatment effectively uncomplicated with treatment to health alternative. First, that not resistance to of the or infections options, for only as oral a patients treatment combat growing the but tract potential no offering has help the other ORLYNVAH urinary these
an very effective is of approval U.S. in marks potent approval for first moment. new class an which treatment speak about a oral in agents delivered penem enables class the as in I'll currently oral of patients desperately the needed. are that drugs, drugs and therapy. the penem a only product approved Having Secondly, more where appropriate community safe the of intravenous
any to vendors Very and interim to the heartfelt who say like in going you ORLYNVAH before the investigators, and moment this further, to take milestone. approval participated I'd interim importantly, and a important a all and consultants colleagues development us thank patients, get helped of and
as oral the and in so approval. resulting and uUTI spend substantial other market the had and Now XXXXs. products more. XX%, XX U.S. as few approaching having in more used are the of The XXXXs sharing in about the and market, product rates rates, these leading I'd launched the was we urinary used Nitrofurantoin, in minutes products resistance volumes the to run The ORLYNVAH tract the approved XX% uncomplicated you market treatment use over rates new resistance high oral of has time like approved with majority has were to in those widely rising excited can a The infection a XXXX, led not most in being why with years. the products in or
products physicians rate eroded time. be of urinary high uncomplicated resistance most tract challenge these increasing empirically, a oftentimes efficacy As are creates since prescribing for to the continuing occurs this practicing very and infections for over
may use as physicians their they have like this work in again forced been some physicians has to widely of in for all almost their concerns choice area therapy as treating use. been that that agents challenges the create for would patients. there Unfortunately, market well since innovation not decades, to almost of agent safety Additionally, this oral products used to as have no in
This or with there these older, most substantial or resistance We a approval, oral and following With many define patients or are patients. as options negatively any history the options existing XX patients patients of no specifically elevated women challenged elevated with their that diabetes have as who that treatment We risk immune could are infections, there oral that this their impact categories: given profiles of other are have risk risk have as to into that patients at believe treat recurrent category, effectively or fall who those many treatment an women women fall available. limited be drug-resistant co-morbidities hurdles. now for of have ORLYNVAH safety are option well patients who that alternative into physicians the systems. group
an group new, urinary tract infection key clinical commonly treatment we pathogens had of treating year patients that resistant patients across could U.S., REASSURE approximately all in oral of that patients and used found that an are alternatives and our these need to in significant efficacious have that resistant completed conducted antibiotics. well. antibiotics. the X% uncomplicated as safe role are patients this of to available in important oral patients, these exclusively almost In Another was isolate earlier X,XXX all ORLYNVAH the oral trial play
the a U.S. like about market I'd Now talk the to uncomplicated urinary for moment tract in
adult urinary research. of of First, tract lifetime. available quick facts infection a couple in will their Approximately XX% women a based have on
valuable will a in we be A million of XX for infections research, tract annually. with ORLYNVAH estimate representing risk X/X category. women prescriptions urinary on estimated of very XX that is an a those have approximately million Based that may size elevated where patients represent history prescriptions uncomplicated their particularly patients, market uncomplicated XX% total infections urinary tract of large, of to recurrence for up infection. Additionally,
President to Dr. and Iterum's about to Steve I'd Now the Head over label. Aronin, like Vice speak Senior turn Clinical of to Development, call ORLYNVAH's
